A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It

The transactions involved 795 shares sold for an estimated total value of about $216,000.

The disposition reduced Michael Burkes Brophy's direct equity holdings by 2%.

The activity was non-discretionary, executed to satisfy tax withholding obligations associated with the vesting of restricted stock units under a Rule 10b5-1 plan.

Michael Burkes Brophy, the chief financial officer of Natera, Inc. (NASDAQ:NTRA) , sold 795 shares of common stock at $271.74 per share in transactions executed on August 3 and August 4, according to a recent SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average sale price ($271.74); post-transaction value based on the August 4 market close ($275.19).

Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it as a significant player in the reproductive health and oncology diagnostics markets. The company's competitive advantage derives from its proprietary testing platforms and expanding clinical applications across multiple therapeutic areas. With a presence in Austin, Natera continues to scale its operations to capture growing demand for non-invasive and precision diagnostic solutions.

Brophy sold on Monday and Tuesday, just before Natera reported earnings on Thursday (after the market closed) and right at the edge of the window that typically closes ahead of results. That timing, plus the tiny size, points to exactly what the filing says it is, tax withheld on vesting shares under a preset plan, not a finance chief front-running his own report. He kept 51,637 shares worth better than $14 million, so nothing here dents his stake. The report that followed his sales was a strong one. Natera grew second-quarter revenue about 38% to $753 million, well past expectations, powered by its Signatera cancer-detection test, and raised full-year guidance by $100 million. That guidance is Brophy's own, and he framed it cautiously, telling investors it "assumes stable Signatera pricing" through the rest of the year, leaving room for upside if prices keep climbing. Signatera's average selling price sat near $1,275 last quarter against a long-term target of roughly $2,000, so the single biggest lever on Natera's growth is a price that still has far to run, and that’s even more good news for long-term investors.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Natera wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.